Menu
Not yet recruiting NCT06986538

Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance

No phase Interventional Advanced Right-sided Colon Cancer the Extent of Lymph Node Dissection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Clearance with the left side of the SMV as the medial boundary, Clearance with the left side of the SMA as the medial boundary.
Who it may be relevant to
Registry conditions: Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Multicenter Randomized Controlled Study of the Extent of Lymph Node Dissection for Advanced Right-sided Colon Cancer

Overview

This is a prospective multicenter randomized controlled clinical study to explore the extent of lymph node dissection in progressive right hemicolon cancer and to elucidate the pattern of lymphatic drainage in the right hemicolon.

Interventions

  • Procedure Clearance with the left side of the SMV as the medial boundary
    Undergo radical resection for right colon cancer with the left side of the SMV as the medial boundary
  • Procedure Clearance with the left side of the SMA as the medial boundary
    Undergo radical resection for right colon cancer with the left side of the SMA as the medial boundary

Primary outcome measures

  • Disease-Free Survival [Time frame: The third postoperative year]
Secondary outcome measures (1)
  • overall survival [Time frame: The third postoperative year]

Eligibility criteria

Inclusion criteria

  • Age: 18-75 years
  • Preoperative pathologic confirmation of adenocarcinoma
  • Tumor located in the region from the ileocecal valve to the right one-third of the transverse colon
  • American Society of Anesthesiologists (ASA) physical status classification I to III
  • Patients who have not received preoperative radiotherapy, chemotherapy, or immunotherapy
  • Preoperative imaging staging cT4N0M0 or cT3-4N+M0
  • Willing to participate in the study and sign the informed consent form

Exclusion criteria

  • Past medical history of malignant tumor
  • Patients with multiple primary tumors
  • Patients with a history of inflammatory bowel disease or familial adenomatous polyposis
  • Patients with distant metastasis
  • Pregnant or breastfeeding women
  • History of other previous major abdominal surgery
  • Patients requiring emergency surgery (including tumor perforation, obstruction, hemorrhage, etc.)
  • Those with other clinical and laboratory conditions deemed by the investigator to be inappropriate for participation in the trial

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 26 centers
  • Cancer Hospital, Chinese Academyof Medical Sciences — Beijing
  • Peking University People's Hospital — Beijing
  • Fujian Medical University Affiliated Union Hospital — Fuzhou
  • Guangdong Provincial People's Hospital — Guangzhou
  • the First Affiliated Hospital of Sun Yat-sen University — Guangzhou
  • Sun Yat-sen University Cancer Hospital — Guangzhou
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine — Guangzhou
  • Nanfang Hospital, Southern Medical University — Guangzhou
  • … and 18 more centers

Identifiers

NCT: NCT06986538 · MARCH

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗